MedTrace Logo

Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients

NCT04594330 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-10-20

No results posted yet for this study

Summary

Virgin Coconut Oil (VCO) contains multiple compounds which have antibacterial, antiviral, and immunomodulatory properties. The role of VCO as an antivirus to treat COVID-19 requires further studies. A previous study has investigated the used of 30 ml of VCO to healthy volunteers for a month and reported no side effect. Here the investigators conduct a pilot trial to investigate the effect of VCO towards the clinical outcomes of COVID-19 patients in Indonesia.

Conditions

  • Coronavirus Infections

Interventions

DRUG

virgin coconut oil (VCO)

15 mL of VCO twice a day for 14 days

OTHER

placebo

15 mL of placebo twice a day for 14 days

Sponsors & Collaborators

  • Gadjah Mada University

    lead OTHER

Principal Investigators

  • Ika Trisnawati, MD, MSc, internist · Gadjah Mada University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04594330 on ClinicalTrials.gov